Aisel Health's 1.7M euro pre-seed bets psychiatry's bottleneck is recall, not typing

Aisel Health, a Copenhagen company building what it calls a clinical operating system for psychiatry, has raised 1.7 million euros in pre-seed funding led by Caesar Ventures ^{[1] [2]}. The size of the round matters less than the wager underneath it: that the constraint in psychiatric care is not producing the session note but retrieving what was in the previous ones ^[3].

That is a deliberate rejection of the dominant product category. According to the company's framing, psychiatrists can already generate notes quickly, and the hard part is finding information from earlier sessions, so Aisel is targeting retrieval rather than documentation speed ^[3]. The product converts interview recordings, documents and patient accounts into structured insights clinicians can reach during a consultation ^[4]. Aisel was founded in 2024 by chief executive Augusta Klingsten Peytz and chief product officer Christian Houen ^[5]. Houen puts the problem as the unsolved human limit of understanding everything ever written about every patient ever treated ^[6].

The comparison set is better capitalised. London-based Limbic has raised around 14.7 million dollars, with a Series A led by Khosla Ventures ^[7]; UK-based Thymia has raised 2.7 million dollars for gamified mental health assessments ^[8]; Berlin's Likeminded has 1.5 million euros and works in corporate wellness rather than clinical documentation ^[9]. The nearest competitors on the source's own reading are JotPsych, with 5 million dollars for an AI behavioural health EHR, and Scribenote, with 8.2 million dollars for veterinary scribe products, both principally about faster note-taking ^[10]. Those four dollar-denominated raises come to roughly 30.6 million dollars between them ^[1]. A differentiation story is cheap at pre-seed; the incumbents' advantage is that they are already inside workflows, and a retrieval layer has to be worth opening the software procurement conversation again.

The market number attached to the round deserves less weight than the operational one. The source cites a mental health technology market projected to reach 10.08 billion dollars by 2025, growing 18.7 percent annually through 2035 on AI adoption and rising demand ^[11], which is a forecast to a year already behind us. The figure that describes the actual problem is that patients still wait weeks or months for appointments in both private and public sectors ^[12]. The source's closing test is the right one: an operating system for psychiatry should reduce waiting lists rather than add another clinic platform ^[13].

Evidence so far is early-stage and Danish. Aisel is working with private clinics in Denmark, running research partnerships with Region H and the University of Southern Denmark, and working with MedTech Growth at the Technical University of Denmark ^[14]. Caesar Ventures was joined by Nordic Web Ventures, LifeX, Angel Invest and returning investors Rockstart and EIFO ^[15]. Carolin Gabor, managing partner at Caesar Ventures and the 2025 KfW Capital Award winner for best female investor, is leading the round and calls psychiatry among healthcare's largest and most overlooked problems ^{[16] [17]}.

The money goes to clinical and engineering hires and to a UK push, where Aisel already serves private psychiatry clients, ahead of a planned seed round ^{[18] [19]}.

Watch whether the UK entry stays inside private psychiatry or reaches referral pathways where waiting lists actually sit, since that is the metric the company has invited ^{[19] [13]}. Watch whether the Danish research partnerships produce published throughput or outcome data before the seed ^[14]. And watch how quickly the note-taking vendors describe retrieval as a feature rather than a category.